Summary (tl;dr)

Viatris Specialty LLC has initiated a nationwide recall of a specific lot of Xanax (alprazolam) 3 mg extended-release tablets because the pills failed dissolution specifications, potentially leading to reduced effectiveness.

Essential Background

Xanax, also known by its generic name alprazolam, is a widely prescribed benzodiazepine medication used to treat anxiety and panic disorders. The U.S. Food and Drug Administration (FDA) is responsible for monitoring the safety and efficacy of pharmaceutical products in the United States and issues recalls when products do not meet quality standards or pose health risks.

The Full Story

A nationwide recall of one lot (Lot 8177156) of Xanax XR (alprazolam) Extended-release Tablets, 3 mg, distributed by Viatris Specialty LLC, was announced due to the pills failing dissolution specifications. This means the tablets may not dissolve properly in the body, which could reduce the amount of active medication absorbed and potentially diminish its therapeutic effect. The recall was initially launched on March 17, 2026, and later classified as a Class II recall by the FDA on April 8, 2026. A Class II recall indicates that exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The affected product, packaged in 60-tablet bottles with an expiration date of February 28, 2027, was distributed in the U.S. between August 27, 2024, and May 29, 2025. The tablets were produced in Ireland.

Why It Matters

This recall is trending because individuals who rely on Xanax for managing anxiety and panic disorders could experience reduced effectiveness from the recalled tablets, potentially leading to inadequate symptom control. While the immediate risk of serious adverse health consequences is considered remote, patients are advised to consult their healthcare providers regarding the recalled lot to ensure they continue to receive appropriate and effective treatment.

Geographic Location

• Ireland (manufacturing location of the recalled Xanax XR tablets)
• Morgantown, Monongalia County, West Virginia, United States (distribution by Viatris Specialty LLC)
• United States (nationwide distribution of the recalled product)